Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
•
Primary Care
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
How would you approach patients with high-risk localized prostate cancer (per STAMPEDE criteria) receiving RT and concurrent ADT but are unable to tolerate abiraterone secondary to toxicities?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
